Hemophilia A – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Hemophilia A – Pipeline Review, H2 2019’, provides an overview of the Hemophilia A pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hemophilia A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Hemophilia A

– The report reviews pipeline therapeutics for Hemophilia A by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Hemophilia A therapeutics and enlists all their major and minor projects

– The report assesses Hemophilia A therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Hemophilia A

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hemophilia A

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alveron Pharma

ApcinteX Ltd

Apitope International NV

ASC Therapeutics Inc

Ascension Healthcare Plc

Beijing Northland Biotech Co Ltd

Beijing Tiantan Biological Products Co Ltd

BioMarin Pharmaceutical Inc

Cabaletta Bio Inc

Casebia Therapeutics

Catalyst Biosciences Inc

Chugai Pharmaceutical Co Ltd

CSL Ltd

Daiichi Sankyo Co Ltd

DBV Technologies SA

Dnarx LLC

EpiVax Inc

Expression Therapeutics LLC

Freeline Therapeutics Ltd

GC Pharma

Generation Bio Corp

Genzyme Corp

ID Pharma Co Ltd

Idogen AB

Immusoft Corp

Innovare R & D SA De CV

Kaifeng Pharmaceutical (Group) Co Ltd

Kymab Ltd

LambdaGen Therapeutics

LFB SA

NovalGen Ltd

Novo Nordisk AS

Octapharma AG

OPKO Biologics Ltd

Pangen Biotech Inc

Pfizer Inc

Pharming Group NV

Precision Biosciences Inc

ProFactor Pharma Ltd

Recursion Pharmaceuticals Inc

Sangamo Therapeutics Inc

Sanofi

Serpinx BV

Shenzhen Weiwu Guangming Biological Preparations Co Ltd

Sigilon Therapeutics Inc

Sino Biopharmaceutical Ltd

Sinocelltech Ltd

Spark Therapeutics Inc

Takeda Pharmaceutical Co Ltd

TeraImmune Inc

Ultragenyx Pharmaceutical Inc

UniQure NV

XL-protein GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hemophilia A (Factor VIII Deficiency) - Overview

Hemophilia A (Factor VIII Deficiency) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hemophilia A (Factor VIII Deficiency) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hemophilia A (Factor VIII Deficiency) - Companies Involved in Therapeutics Development

Alveron Pharma

ApcinteX Ltd

Apitope International NV

ASC Therapeutics Inc

Ascension Healthcare Plc

Beijing Northland Biotech Co Ltd

Beijing Tiantan Biological Products Co Ltd

BioMarin Pharmaceutical Inc

Cabaletta Bio Inc

Casebia Therapeutics

Catalyst Biosciences Inc

Chugai Pharmaceutical Co Ltd

CSL Ltd

Daiichi Sankyo Co Ltd

DBV Technologies SA

Dnarx LLC

EpiVax Inc

Expression Therapeutics LLC

Freeline Therapeutics Ltd

GC Pharma

Generation Bio Corp

Genzyme Corp

ID Pharma Co Ltd

Idogen AB

Immusoft Corp

Innovare R & D SA De CV

Kaifeng Pharmaceutical (Group) Co Ltd

Kymab Ltd

LambdaGen Therapeutics

LFB SA

NovalGen Ltd

Novo Nordisk AS

Octapharma AG

OPKO Biologics Ltd

Pangen Biotech Inc

Pfizer Inc

Pharming Group NV

Precision Biosciences Inc

ProFactor Pharma Ltd

Recursion Pharmaceuticals Inc

Sangamo Therapeutics Inc

Sanofi

Serpinx BV

Shenzhen Weiwu Guangming Biological Preparations Co Ltd

Sigilon Therapeutics Inc

Sino Biopharmaceutical Ltd

Sinocelltech Ltd

Spark Therapeutics Inc

Takeda Pharmaceutical Co Ltd

TeraImmune Inc

Ultragenyx Pharmaceutical Inc

UniQure NV

XL-protein GmbH

Hemophilia A (Factor VIII Deficiency) - Drug Profiles

Hemophilia A - Dormant Projects

Hemophilia A - Discontinued Products

Hemophilia A - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Hemophilia A (Factor VIII Deficiency) – Pipeline by Alveron Pharma, H2 2019

Hemophilia A (Factor VIII Deficiency) – Pipeline by ApcinteX Ltd, H2 2019

Hemophilia A (Factor VIII Deficiency) – Pipeline by Apitope International NV, H2 2019

Hemophilia A (Factor VIII Deficiency) – Pipeline by ASC Therapeutics Inc, H2 2019

Hemophilia A (Factor VIII Deficiency) – Pipeline by Ascension Healthcare Plc, H2 2019

Hemophilia A (Factor VIII Deficiency) – Dormant Projects, H2 2019

Hemophilia A (Factor VIII Deficiency) – Dormant Projects, H2 2019 (Contd..1), H2 2019

Hemophilia A (Factor VIII Deficiency) – Dormant Projects, H2 2019 (Contd..2), H2 2019

Hemophilia A (Factor VIII Deficiency) – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Hemophilia A (Factor VIII Deficiency), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports